SCHEMBL273883

SCHEMBL273883

O=C(Nc1ccc(Cl)cc1C(=O)N/N=C/c1ccc(Cl)c(C(F)(F)F)c1)c1cccc(CSc2nc[nH]n2)c1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 10/20 0.52
SLC34A1 Q06495 1/20 0.52
SLC34A3 Q8N130 1/20 0.52
SLC20A1 Q8WUM9 1/20 0.52
ADCYAP1R1 P41586 5/20 0.40
NPC1 O15118 3/20 0.38
MAPT P10636 3/20 0.38
RAB9A P51151 3/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HSPH1 Q92598 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266942 1.00 SLC34A2 (0.52) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL273976 0.93 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL266177 0.93 SLC34A2 (0.44) SLC34A2SLC34A1SLC34A3SLC20A1ADCYAP1R1
SCHEMBL273762 0.89 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1NPC1
SCHEMBL266119 0.89 SLC34A2 (0.57) SLC34A2SLC34A1SLC34A3SLC20A1NPC1
SCHEMBL267566 0.88 SLC34A2 (0.66) SLC34A2SLC34A1SLC34A3SLC20A1NPC1
SCHEMBL273534 0.88 SLC34A2 (0.66) SLC34A2SLC34A1SLC34A3SLC20A1NPC1
SCHEMBL274195 0.87 SLC34A2 (0.52) SLC34A2SLC34A1SLC34A3SLC20A1NPC1
SCHEMBL268533 0.87 SLC34A2 (0.52) SLC34A2SLC34A1SLC34A3SLC20A1NPC1
SCHEMBL269093 0.87 SLC34A2 (0.55) SLC34A2SLC34A1SLC34A3SLC20A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.